MC PARTNERS INC.

MANAGEMENT DISCUSSION AND ANALYSIS

AMENDED AND RESTATED

FOR THE NINE MONTHS ENDED AUGUST 31, 2012

MC PARTNERS INC.

Management's Discussion and Analysis

The following management discussion and analysis (MD&A) of the financial information of MC Partners Inc. (the "Company") and results of operations should be read in conjunction with the unaudited condensed interim financial statements and accompanying notes for the nine months ended August 31, 2012 and the audited financial statements and accompanying notes as at November 30, 2011 and for the period from January 28, 2011 (date of incorporation) to November 30, 2011. The audited financial statements and the unaudited condensed interim financial statements, together with the following MD&A are intended to provide investors with a reasonable basis for assessing the financial performance of the Company as well as forward-looking statements relating to future performance. The unaudited condensed interim financial statements are prepared in accordance with IAS 34 – Interim Financial Reporting ("IAS 34") and include the financial performance of the Company.

The Company's critical accounting estimates, significant accounting policies and risk factors have remained substantially unchanged and are still applicable to the Company unless otherwise indicated. All amounts are expressed in Canadian Dollars unless noted otherwise.

Forward-Looking Statements

Certain statements contained in this MD&A may constitute forward-looking statements. These forward-looking statements can generally be identified as such because of the context of the statements, including such words as "believes", "anticipates", "expects", "plans", "may", "estimates", or words of a similar nature. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from anticipated future results and/or achievements expressed or implied by such forward-looking statements, which speak only as of the date the statements were made. Readers are therefore advised to consider the risks associated with any such forward-looking statements, which speak only as of the date the statements were made, and readers are advised to consider such forward-looking statements in light of the risks set forth herein.

Overview

The Company was incorporated on January 28, 2011 pursuant to the *Business Corporations Act*, British Columbia, and is a capital pool company as defined by Policy 2.4 (the "CPC Policy") of the TSX Venture Exchange (the "Exchange"). The Company's registered office is Suite 300 – 576 Seymour Street, Vancouver, BC, Canada. The principal business of the Company is to identify and evaluate business opportunities with the objective of completing the acquisition of an interest in properties, assets or a business ("Qualifying Transaction" or "QT") under Exchange rules. Under these rules, a Qualifying Transaction must be entered into within 24 months of listing.

Additional information relating to the Company can be found on the SEDAR website at www.sedar.com.

Date of Report

December 19, 2012

Overall Performance

On May 3, 2012, the Company completed its initial public offering of 5,000,000 common shares at a price of \$0.10 per share for gross proceeds of \$500,000. Share issuance cash costs totaled \$111,545, for net proceeds of \$388,455.

In addition, in connection with the initial public offering, the Company granted agent's options to purchase 500,000 common shares at a price of \$0.10 per share, expiring May 3, 2014.

On March 15, 2012, the Company adopted a stock option plan, which provides that the Board may from time to time, in its discretion, and in accordance with the Exchange requirements, grant to directors, officers, employees and consultants of the Company (the "Service Providers"), non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares exercisable for five years from the date of grant.

On May 3, 2012, the Company granted 700,000 stock options to its officers and directors. The options are exercisable at a price of \$0.10 per share, expiring on May 3, 2017.

On October 12, 2012 the Company sent a request to the Exchange to halt the Company shares from trading pending news and will recommence at such time as the Exchange may determine, based on the satisfaction of certain requirements pursuant to TSX Venture Exchange Policy 2.4.

On October 17, 2012, the Company released a press release stating that it had reached an agreement in principle (the "Agreement") to acquire all of the issued and outstanding shares of bioMmune Technologies Inc. ("BIO"). Under the terms of the Agreement, the Company will issue to the shareholders of BIO a total of 5,600,000 shares of the Company at a price of \$0.15 per share, to be issued at the closing.

The Agreement is subject to Exchange approval and will constitute the Company's QT for the purposes of the CPC policies of the Exchange. On conclusion of the proposed QT, the Company will change its name to reflect the nature and character of the business of BIO, with the resulting issuer trading as a Tier 2 Research and Development Issuer on the Exchange. Subject to the discretion of the Exchange, the proposed QT does not constitute a Non-Arms' Length Transaction under the Policies of the Exchange.

BIO is a private British Columbia company that was formed to commercially exploit a number of patents and patent applications that surround three technologies.

The first technology involves the discovery of HDACi's (Histone Deacetylase) which are proteins (enzymes) important for the regulation of cell growth and have been found to be novel drugs for the treatment of cancers. BIO plans to discover new HDACi inhibitors, which will be active and recognize cancer cells and results in the body's immune system being able to kill the cancer cells.

The second technology deals with Calcium Channels which are a multi member family with over 10 different proteins. These channels activities are regulated and regulate the concentration of calcium (Ca) in different places in cells and regulates the concentration of Ca which is very important for the activity of cells involved in the immune system. This channel, designed as Cav 1.4, is important and identifying new calcium channel regulators (blockers) will be important to improve the activity of the immune system to combat cancers, infections and also autoimmunities.

The third technology is called CD74 which is a protein involved in the immune system and its regulation. Finding ways or compounds that regulate its activity will improve the immune system to combat infections, cancers and autoimmune diseases.

The closing of this transaction is subject to a number of conditions, including: (i) the execution of a definitive agreement; (ii) completion of successful due diligence by the parties, (iii) the Company successfully completing a financing for gross proceeds of a sufficient amount to fund the business plan and to meet the minimum listing requirements of the Exchange, (iv) Exchange approval and (v) shareholder approval, if required.

Sponsorship of a Qualifying Transaction of a capital pool company is required by the Exchange unless exempt in accordance with Exchange policies. The Company intends to retain a qualified sponsor as soon as is reasonably practicable to act as its sponsor in connection with the QT in accordance with Exchange Policy 2.2.

On October 17, 2012, the Company also announced its intention to complete a private placement of 10,000,000 units of the Company at a price of \$0.15 per unit for gross proceeds of \$1,500,000 (the "Financing"). Each unit will consist of one common share of the Company and one common share purchase warrant of the Company (the "Warrant"). Each whole Warrant will entitle the holder to purchase one additional common share of the Company at a price of \$0.25 for a period of 12 months from the completion of the Financing

The press release dated October 17, 2012 can be viewed under the Company's profile at www.sedar.com.

The Company has not generated any revenues and has incurred losses of \$76,133 since inception. The ability of the Company to continue as a going concern depends upon the acquisition of a successful project and also on the ability of the Company to obtain necessary financing to fund ongoing operations. The Company's ability to achieve these objectives cannot be determined at this time.

The statement of financial position as of August 31, 2012 indicates a cash position of \$451,270 (November 30, 2011 - \$61,253). The increase resulted from the completion of the Company's initial public offering for net proceeds of \$388,455.

Other current assets comprise prepaids of \$1,000 (November 30, 2011 - \$34,377) related to the Company's initial public offering.

Current liabilities at August 31, 2012 total \$3,448 (November 30, 2011 - \$10,077) consisting of general office expenses.

Shareholders' equity is comprised of share capital of \$488,455 (November 30, 2011 - \$100,000) and a deficit of \$39,633 (November 30, 2011 - \$14,447).

As at August 31, 2012, the Company had working capital of \$448,822 (November 30, 2011 - \$85,553).

The weighted average number of common shares outstanding for the nine months ended August 31, 2012 is 2,138,182 (November 20, 2011 – Nil). In May, 2012, the Company issued 7,000,000 common shares upon completion of its initial public offering.

Results of Operations

During the three months ended August 31, 2012, the Company reported a net loss of \$40,601 (\$0.00 basic and diluted loss per share) compared to a net loss of \$1,421 (\$0.00 basic and diluted loss per share) reported for the same period in fiscal 2011. The net loss comprised listing and transfer agent fees, travel and entertainment, accounting fees and general office expenses.

Selected Financial Information - Summary of Quarterly Results

The following table presents unaudited selected quarterly financial information of the Company for the seven most recently completed quarters of operation since incorporation. This information is derived from unaudited condensed interim financial statements prepared by management. The Company's condensed interim financial statements are prepared in accordance with IAS 34 and expressed in Canadian Dollars unless otherwise stated.

	2012			2011				2010
	Qtr 3	Qtr 2	Qtr 1	Qtr 4	Qtr 3	Qtr 2	Qtr 1*	Qtr 4
	\$	\$	\$	\$	\$	\$	\$	\$
Revenue	-	-	-	-	-	-	-	NA
Net Loss	(40,601)	(20,304)	(781)	(12,869)	(1,421)	(52)	(105)	NA
Basic and diluted								
Loss per share	(0.01)	(0.01)	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)	NA

^{*} January 28, 2011 (date of incorporation) to February 28, 2011.

The Company's significant accounting policies are set out in Note 3 of the audited annual financial statements for the period from January 28, 2011 (date of incorporation) to November 30, 2011 and Note 2 to the unaudited condensed interim financial statements for the nine months ended August 31, 2012.

Statement of Operations

	Nine Months ended August 31,		Initial period from January 28, 2011 (date of incorporation) to August 31,		Three months ended August 31,			
		2012		2011		2012		2011
Expenses								
Accounting fees	\$	8,466	\$	-	\$	2,260	\$	-
Administrative and general office		1,412		95		116		95
Legal fees		-		1,223		-		1,223
Share-based payment		36,500		-		36,500		-
Transfer agent, filing and listing fees		14,239		-		1,550		-
Travel and entertainment		1,069		260		175		103
Net Loss and Comprehensive Loss for the								
Period	\$	61,686		1,578	\$	40,601	\$	1,421
Basic and Diluted Loss per Share	\$	0.03	\$	-	\$	0.01	\$	-
Weighted Average Number of Common Shares Outstanding	;	2,138,182		-		4,900,000		-

Year over year expenses have increased primarily due to the completion of the initial public offering.

Liquidity & Capital Resources

The Company has financed its operations to date through the issuance of common shares.

	August 31, 2012		November 30, 2011		
Working capital Deficit	\$ 448,8 \$ 76,1		85,553 14,447		

During the nine months ended August 31 2012, net cash used in (from) operating activities was \$(1,562) (August 31, 2011 – \$20,906) comprising a loss of \$61,686 (August 31, 2011 - \$1,578), a non cash item, share-based payment of \$36,500, a decrease in prepaids of \$33,377 (August 31, 2011 – an increase of \$19,778) and a decrease in accounts payable of \$6,629 (August 31, 2011 – an increase of \$450).

Net cash from financing activities for the nine months ended August 31, 2012 is \$388,455 (August 31, 2011 - \$Nil). The Company completed its initial public offering in May, 2012 for net cash proceeds of \$388,455.

The unaudited condensed interim financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company will continue to require funds for future acquisitions as well as to meet its ongoing day-to-day operating requirements and will have to continue to rely on equity and debt financing. There can be no assurance that financing, whether debt or equity will always be available to the Company in the amount required at any particular period or if available, that it can be obtained on terms satisfactory to the Company.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that would potentially affect current or future operations or the financial condition of the Company.

Related Party Transactions

(a) Ultimate controlling party

As at August 31, 2012, there was no ultimate controlling party of the Company.

(b) Key management personnel compensation and director transactions

During the nine months ended August 31, 2012, the Company did not pay any key management personnel compensation.

Directors hold, directly or indirectly, 2,100,000 common shares of the Company.

Proposed Transactions

The Company does not currently have any proposed transactions approved by the Board of Directors. All current transactions are fully disclosed in the unaudited condensed interim financial statements for the nine months ended August 31, 2012.

Financial Instruments & Other Instruments

The Company classifies its cash as financial assets at fair value through profit or loss and accounts payable and accrued liabilities as other financial liabilities. The fair values of accounts payable and accrued liabilities approximate their carrying values due to the short-term nature of these instruments.

The Company classifies its fair value measurements within a fair value hierarchy, which reflects the significance of the inputs used in making the measurements as defined in IFRS 7 – *Financial Instruments – Disclosures*:

Level 1 – Unadjusted quoted prices at the measurement date for identical assets of liabilities in active markets. The Company's cash are measures as level 1 inputs.

Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3 – Significant unobservable inputs which are supported by little or no market activity.

Risks and Uncertainties

Overview

Market risks. The Company's securities trade on public markets and the trading value thereof is determined by the evaluations, perceptions and sentiments of both individual investors and the investment community taken as a whole. Such evaluations, perceptions and sentiments are subject to change, both in short term time horizons and longer term time horizons. An adverse change in investor evaluations, perceptions and sentiments could have a material adverse outcome on the Company and its securities.

Share Price Volatility and Price Fluctuations. In recent years, the securities markets in Canada have experienced a high level of price and volume volatility, and the market prices of securities of many companies, has experienced wide fluctuations which have not necessarily been related to the operating performance, underlying asset values or prospects of such companies. There can be no assurance that these price fluctuations and volatility will not continue to occur.

Key personnel risks. The Company's acquisition efforts are dependent to a large degree on the skills and experience of certain of its key personnel, including the board of directors. The Company does not maintain "key man" insurance policies on these individuals. Should the availability of these persons' skills and experience be in any way reduced or curtailed, this could have a material adverse outcome on the Company and its securities.

History of Net Losses; Accumulated Deficit; Lack of Revenue from Operations. The Company has incurred net losses to date. Its deficit as of August 31, 2012 is \$76,133. The Company has not yet had any revenue. There is no certainty that the Company will produce revenue, operate profitably or provide a return on investment in the future.

Other MD&A Requirements

Information available on SEDAR

As specified by National Instrument 51-102, the Company advises readers of this MD&A that important additional information about the Company is available on the SEDAR website – www.sedar.com.

Disclosure by venture issuer

An analysis of the material components of the Company's general and administrative expenses is disclosed in the financial statements to which this MD&A relates.

Outstanding share data

Common shares issued and outstanding as at August 31, 2012 are described in detail in Note 4 to the audited financial statements for the period from January 28, 2011 (date of incorporation) to November 30, 2011 and Note 4 to the unaudited condensed interim financial statements for the nine months ended August 31, 2012.

As at the date of this document, December 19, 2012, the Company had the following number of securities outstanding:

Issued and outstanding	Quantity	Exercise price	Expiry date	
Common shares	7,000,000	N/A	N/A	
Stock options	700,000	\$0.10	May 3, 2017	
Agent's options	500,000	\$0.10	May 3, 2014	